The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD (ABATE-MASLD)

December 10, 2025 updated by: Shen Feng, Eastern Hepatobiliary Surgery Hospital

The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD Background: a Dual Arm, Multicenter, Randomized Controlled Study

This research plan involves a treatment approach for advanced hepatocellular carcinoma (HCC) in the context of metabolic-associated steatotic liver disease (MASLD). The study aims to compare the efficacy differences between sequential therapy and concurrent therapy using bevacizumab and atezolizumab for advanced HCC in MASLD. The research will focus on evaluating objective response rates, progression-free survival, disease control rates, and overall survival, while utilizing biomarker analysis to elucidate treatment mechanisms. Additionally, the study will examine treatment safety, including the incidence and severity of adverse events.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The study will recruit 20 patients, randomly dividing them into sequential and concurrent groups for up to 6 months of treatment and follow-up. In addition to routine efficacy assessments, the study will analyze changes in the microenvironment before and after treatment, including T-cell calcium levels, VEGFA expression, and immune-related factor alterations. Furthermore, it will explore the relationship between T-cell calcium signaling genes and treatment response, evaluating the impact of baseline metabolic characteristics (such as blood lipids and insulin resistance) on therapeutic outcomes.

In terms of safety, the study will monitor all adverse events (AEs) and serious adverse events (SAEs), and classify them according to the CTCAE 5.0 criteria. During the treatment period, patients will undergo regular liver biopsy to assess changes in the tumor microenvironment. The ultimate goal of the study is to provide evidence-based precision treatment strategies for MASLD-HCC patients.

Study Type

Interventional

Enrollment (Estimated)

20

Phase

  • Phase 2
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 201805

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Eligibility Criteria Inclusion Criteria

  • Age ≥ 18 years old (gender not limited)
  • ECOG performance status of 0-1
  • Preoperative imaging diagnosis of advanced hepatocellular carcinoma (BCLC stage C or D, unsuitable for surgery)
  • Ultrasound or MRI indicating moderate to severe fatty liver (Fibroscan CAP > 268 dB/m or MR fat score > 10%)
  • Willing to use contraceptive measures during the trial period
  • Expected survival time ≥ 3 months
  • At least one measurable lesion (per RECIST 1.1) that has not been irradiated
  • Organ function levels (within 7 days before first study medication) must meet the following:
  • Hematopoietic function: ANC ≥ 1.5×10⁹/L, PLT ≥ 100×10⁹/L, Hb ≥ 90 g/L, no transfusion within 14 days
  • Liver function: TBIL ≤ 1.5×ULN, AST/ALT/ALP ≤ 2.5×ULN, serum creatinine ≤ 1.5×ULN, CrCl ≥ 50 mL/min, ALB ≥ 30 g/L, Child-Pugh A
  • Coagulation function: INR and APTT ≤ 1.5×ULN or within therapeutic range if on anticoagulants
  • Renal function: urinary protein ≤ 1+ (or ≤1 g/24h if >1+)
  • Cardiac function: ECG normal or clinically insignificant, LVEF > 50%
  • Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to first dosing
  • Men and women of reproductive potential must use effective contraception during and for 12 months after treatment
  • Participants must voluntarily provide informed consent and have good compliance

Exclusion Criteria

  • Excessive alcohol consumption (weekly ethanol intake: males < 210 g, females < 140 g)
  • Tumor lesions previously treated with targeted therapy, immunotherapy, TACE, or radiotherapy
  • Pregnant or breastfeeding women, or positive pregnancy test at baseline
  • Central nervous system metastases diagnosed by CT, MRI, or PET-CT
  • Participation in another clinical drug or therapy trial within 4 weeks before first study dose
  • Major surgery within 4 weeks prior to first study dose, or incomplete recovery from surgery
  • Radiotherapy within 2 weeks before first study dose
  • History or presence of primary immunodeficiency or active autoimmune disease
  • History of organ transplantation or hematopoietic stem cell transplantation
  • Current use of immunosuppressants or corticosteroids (>10 mg/day prednisone or equivalent) within 2 weeks
  • Positive for HIV antibody or Treponema pallidum antibody, or active hepatitis B/C infection
  • Allergy to recombinant humanized PD-1 monoclonal antibody, VEGF monoclonal antibody, or components
  • Symptomatic pleural effusion, pericardial effusion, or ascites requiring clinical intervention
  • Severe cardiovascular disease within 12 months (e.g., CAD, CHF ≥ II, arrhythmias, MI)
  • Events within 6 months before first dose (e.g., DVT, PE, MI, PCI, ACS, CABG, stroke, TIA, embolism)
  • History of GI surgery, obstruction, bleeding, dysfunction, or malabsorption affecting drug absorption
  • Severe uncontrolled infection or comorbidity, or moderate/severe renal impairment
  • Active pulmonary disease (interstitial pneumonia, COPD, asthma, tuberculosis history)
  • Abnormal coagulation (INR > 2.0, PT > 16 s), bleeding tendency, or thrombolytic/anticoagulant therapy (except prophylaxis)
  • Significant bleeding within 3 months (e.g., hemoptysis ≥ 2.5 mL, GI bleeding, varices, ulcers, vasculitis)
  • Known hereditary/acquired bleeding or thrombotic disorders (e.g., hemophilia, thrombocytopenia)
  • History of substance abuse or mental disorders affecting compliance
  • Use of warfarin or coumarin derivatives within 14 days before or during treatment
  • Other severe acute/chronic conditions increasing risk or confounding results
  • Poor compliance or other conditions deemed unsuitable for trial participation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Sequential treatment of bevacizumab combined with atezolizumab (sequential group)
Drug: Sequential treatment of bevacizumab combined with atezolizumab (sequential group)
The first cycle (3 weeks) receives bevacizumab monotherapy, and from the second cycle onwards, it is combined with atezolizumab until disease progression or intolerable toxicity.
Active Comparator: Simultaneous treatment of bevacizumab combined with atezolizumab (same period group)
Drug: Simultaneous treatment of bevacizumab combined with atezolizumab (same period group)
Simultaneous treatment of bevacizumab combined with atezolizumab (same period group)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
objective response rate (ORR)
Time Frame: 6 Months
Compare the objective response rate (ORR) of sequential treatment with bevacizumab combined with atezolizumab (sequential group) and concurrent treatment (concurrent group) in advanced HCC under MASLD background, according to RECIST 1.1 criteria.
6 Months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Eastern Hepatobiliary Surgery Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 20, 2025

Primary Completion (Estimated)

August 30, 2026

Study Completion (Estimated)

August 30, 2026

Study Registration Dates

First Submitted

August 17, 2025

First Submitted That Met QC Criteria

December 10, 2025

First Posted (Actual)

December 16, 2025

Study Record Updates

Last Update Posted (Actual)

December 16, 2025

Last Update Submitted That Met QC Criteria

December 10, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • EHBHKY2024-K023-P011
  • 82403243 (Other Grant/Funding Number: National Natural Science Foundation)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on HCC - Hepatocellular Carcinoma

Clinical Trials on Sequential treatment of bevacizumab combined with atezolizumab (sequential group)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Germany

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe